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Colony-Stimulating Factor-1-Dependent Macrophages
Are Responsible for IVIG Protection
in Antibody-Induced Autoimmune Disease
animals that were protected or enhanced, respectively,
for antibody-triggered inflammatory responses (Clynes
et al., 1999; Sylvestre and Ravetch, 1994). These results
suggested that effective intervention in autoantibody-
mediated inflammatory diseases could be achieved by
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tion receptors or inducing expression of the inhibitoryAlbert Einstein College of Medicine
receptor. For example, platelet consumption triggeredNew York, New York 10461
by an anti-platelet antibody in a murine model of immune
thrombocytopenia (ITP) could be prevented by the ad-
ministration of either an anti-FcRIII antibody or intrave-Summary
nous  globulin (IVIG), the latter resulting from its ability
to induce expression of FcRIIB on splenic macro-The ability of IVIG to induce expression of FcRIIB and
phages, thereby preventing FcRIII-mediated clearancethereby prevent antibody-induced inflammation has
of IgG-opsonized platelets in this cytotoxic antibodybeen used as a probe to dissect the effector cell com-
model of ITP (Samuelsson et al., 2001). This property ofponents in the KRNxNOD (K/BxN) arthritis model. IVIG
IVIG was exploited in the present study to investigateprotection resulted from the induction of FcRIIB on
the effector cell components of an immune complex-infiltrating macrophages but not neutrophils, indicat-
mediated inflammatory response, the arthritis displayeding a critical role for macrophage activation in this
by the KRNxNOD F1 mouse (Kouskoff et al., 1996).disease model. Disease induction but not IVIG protec-
Injection of serum from KRNxNOD F1 mice containingtion was observed in CSF-1-deficient mice (op/op) in
high-titer IgG antibodies to glucose-6-phosphate isom-K/BxN arthritis, thus defining different macrophage
erase (GPI) into susceptible hosts leads to the deposi-subsets in these processes. These results suggest a
tion of immune complexes on the cartilage surface andtwo-step model for IVIG protection in which CSF-1-
an inflammatory response characterized by neutrophildependent macrophages act as innate “sensors” for
infiltration and increased vascular permeability (Matsu-the Fc fragment of IVIG, leading to the induction of
moto et al., 1999). Mice deficient in mast cells (w/wv andFcRIIB on CSF-1-independent “effector” macro-
Sl/Sld) (Lee et al., 2002), the low-affinity activation Fcphages thereby raising the threshold required for
receptor, FcRIII, or components of the alternative (butFcRIII activation and preventing autoantibody-trig-
not classical) pathway of complement are protectedgered inflammation.
from the pathogenic effects of K/BxN serum (Ji et al.,
2002). In many respects this reaction is typical of theIntroduction
Arthus reaction, where immune complex deposition trig-
gers localized inflammation in an FcRIII and mast cell-The activation of inflammatory responses by autoanti-
dependent reaction and is independent of the classicalbodies is central to the pathogenesis of many autoim-
pathway of complement activation (Sylvestre and Ra-mune disorders including thrombocytopenia, anemia,
vetch, 1996). Engagement of immune complexes bylupus, rheumatoid arthritis, vasculitis, and dermatomyo-
FcRIII on mast cells in a reverse passive cutaneous
sitis (Bussel, 2000; Dalakas, 2001; Feldmann, 2001; Lip-
Arthus reaction initiated an inflammatory reaction resulting
sky, 2001; Napoli and Freeman, 2001). By engaging acti-
in edema, hemorrhage, and neutrophil infiltration at the
vation Fc receptors for IgG, immune complexes and site of immune complex deposition. This dependence of
cytotoxic antibodies trigger mast cell and macrophage IgG antibodies on the engagement and activation of
activation as well as neutrophil infiltration, leading to FcRIII, which, in turn, is modulated by the coexpression
the hallmarks of an inflammatory response (Ravetch and of FcRIIB, has been widely extended to numerous mod-
Bolland, 2001). These activation responses are balanced els of autoimmunity and antibody-mediated cytotoxicity
through the coexpression of an inhibitory receptor, (Ravetch and Bolland, 2001; Ravetch and Clynes, 1998).
FcRIIB, which shares ligand binding capacity with In the present study we set out to determine the ability
FcRIII but transduces an opposing signal (Dae¨ron, of IVIG to protect susceptible animals from K/BxN se-
1997). The ratio of activation to inhibitory receptor ex- rum-induced arthritis and to identify the mechanism of
pression on a particular cell determines its threshold for this protection. IVIG is effective at protecting mice from
response to IgG antibodies as well as provides for a arthritis induced by K/BxN serum; this protection was
mechanism for terminating activation responses. This dependent on expression of FcRIIB, as was seen in
system provides the dominant in vivo pathway for de- the ITP model (Samuelsson et al., 2001), and resulted
termining the capacity of an IgG antibody to mediate from induction of its expression on macrophages in the
an inflammatory response. Targeted deletion of either synovial space, indicating that immune complex en-
the activation or inhibitory IgG Fc receptor resulted in gagement of FcRs on macrophages is a key step in the
development of disease. The mechanism of FcRIIB
induction required the presence of colony-stimulating*Correspondence: ravetch@rockefeller.edu
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Figure 1. IVIG or Its Fc Portion Protects against K/BxN Serum-Induced Arthritis
(A) Wt BALB/c mice were injected with PBS, K/BxN serum alone, or IVIGK/BxN serum at day 0. IVIG (1 g/kg) was injected 1 hr before (red
arrow) or 48 hr after (open arrow) injection of K/BxN serum. Arthritis was evaluated by measuring clinical index (A) and ankle thickening (D)
(see Experimental Procedures); mean results are presented.
(B) Hind limbs of representative wt BALB/c mice at day 6 after PBS, K/BxN serum, or IVIGK/BxN serum injection. Only the K/BxN serum-
treated mice show severe inflammation of the hind paw.
(C and D) Mean results of arthritis score (C) and ankle thickness (D) from IVIG-Fc portion  K/BxN serum-treated and IVIG-Fab portion 
K/BxN serum-treated mice are presented. Data from representative (three to five mice per group), multiple experiments are shown.
factor-1 (CSF-1) -dependent macrophages in both arthritis in treated animals (Figure 1A). The anti-inflam-
matory effect of IVIG was conferred solely by the FcK/BxN arthritis and ITP, indicating that the pathway of
fragment, with Fab treatment conferring no protectionprotection is not a direct effect on the effector macrophage
on K/BxN induced inflammation (Figures 1C and 1D).but rather a multistep process involving both CSF-1-
K/BxN arthritis displays an absolute requirement fordependent and -independent macrophage subsets.
the low-affinity activation FcRIII receptor, as mice defi-
cient in this receptor do not develop disease (Figure
Results 3A). Increasing the serum dose by a factor of four and
extending the observation to 12 days did not reveal
Balb/c mice were injected with K/BxN serum alone or any evidence of pathology (data not shown). Previous
with IVIG 1 hr prior to receiving K/BxN serum and scored studies, using a different FcRIII knockout (Hazenbos
for the appearance of arthritis, as measured either by et al., 1996), showed a mild disease phenotype (Corr
ankle thickness or arthritis score. Mice that received and Crain, 2002; Ji et al., 2002), which we attribute to
K/BxN serum alone developed arthritis starting day 2 an incomplete deficiency of FcRIII expression in that
postinjection and were sustained for greater than 10 knockout strain. This interpretation is supported by the
days. IVIG-treated mice were protected from the devel- protection seen in the common  chain knockout (defi-
opment of arthritis, measured by arthritis score (Figure cient in both FcRI and III), which is identical to the
1A), ankle thickness (Figure 1D), or by histological exam- FcRIII knockout we report here. Since the high-affinity
ination (Figure 2). Synovitis and neutrophil infiltration, a activation FcRI receptor is not required for disease
hallmark of this disease model (Kouskoff et al., 1996; development (Figure 3B), the protection observed is
Wipke and Allen, 2001), was apparent by day 3 and thus attributable solely to FcRIII. FcRI-deficient mice
maximal by day 6 after K/BxN serum treatment. Adminis- develop disease with a time course and severity equiva-
tration of IVIG attenuated synovial infiltration at day 3 lent to that seen in its wild-type control 129/B6 mice (Ji
and by day 6 was undetectable. Recruitment of neutro- et al., 2002 and data not shown) and are protected by
phils can be seen in a marginal rim at the interface of IVIG. In contrast, FcRIIB deficient mice either on B6
the synovial lining and the synovial fluid in K/BxNIVIG or Balb/c backgrounds develop a more severe disease
treated mice, which, however, fails to progress to frank compared to wild-type littermates (Figures 3C and 3D
infiltration. IVIG was able to reverse an ongoing inflam- and as previously reported [Corr and Crain, 2002]) and
matory response—injection of IVIG 2 days after induc- are unable to respond to IVIG protection (Figures 3C
and 3D). These results indicate that the mechanism oftion with K/BxN serum resulted in a rapid reversal of
Macrophages Enable IVIG Protection from Arthritis
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Figure 2. IVIG Induces Progressive Clearance of Inflammatory Cells in Ankle Joints in K/BxN Serum-Induced Arthritis
Hematoxylin-eosin staining of ankle sections of PBS-treated, K/BxN serum-treated, or IVIGK/BxN serum-treated mice after 3 days (left
panels) and 6 days (right panels). c, cartilage; s, synovium; sl, synovial lining; sf, synovial fluid. In PBS-treated mice, the synovial fluid at day
3 or 6 is acellular (low magnification), and the synovial lining is unicellular (high magnification). In K/BxN serum-treated and IVIGK/BxN
serum-treated mice, synovitis is apparent at day 3; inflammatory cells invade the synovium and exude into the synovial fluid. Examination of
ankle sections of multiple mice showed a slight to marked reduction of the synovium infiltration in IVIG-treated mice at day 3. At day 6, severe
synovitis and massive infiltration of neutrophils is present in mice treated with K/BxN serum alone but not IVIGK/BxN serum-treated mice.
In the latter, the synovium is cleared from inflammatory cells (low magnification) and only a multicellular synovial lining and inflammatory cell
aggregate exudates persist in the synovial fluid.
IVIG protection through FcRIIB is not restricted to ITP requirement for CSF-1-dependent macrophages in IVIG
protection was also observed in ITP (data not shown).(Samuelsson et al., 2001), in which anti-platelet antibod-
ies trigger platelet consumption through splenic macro- Indeed, platelet consumption was observed in op/op
mice when exposed to passive anti-platelet antibodyphages (Mizutani et al., 1993) but is a more general
mechanism not restricted to specific antibodies or to immunization, and, as described above for K/BxN in-
duced arthritis, IVIG protection is lost. Our results indi-the sites of inflammation.
Since IVIG results in an increase of the macrophage cate that IVIG protection in both arthritis and ITP requires
the presence of CSF-1-dependent macrophage subsetspopulations expressing FcRIIB in the ITP model (Sam-
uelsson et al., 2001), we investigated whether this mech- that are absent in op/op mice. These mice exhibit multiple
tissue-specific losses of macrophage subsets as com-anism would also account for IVIG activity in the K/BxN
arthritis model. We therefore investigated the cellular pared to wild-type animals and also display a moderate
lymphopenia (Cecchini et al., 1994). Since IVIG protec-requirements for protection in both K/BxN arthritis and
ITP by examining IVIG protection in a variety of mouse tion of antibody-induced arthritis does not require B or
T cells (Figure 3E and data not shown), this lymphopeniastrains deficient for specific immune subsets. As seen
in Figures 3E and 3F, K/BxN serum-induced arthritis should not account for the absence of IVIG protection
in op/op mice. Since antibody-mediated inflammationdeveloped in the absence of B cells (IgH/), T cells (as
published, Korganow et al., 1999), and CSF-1-depen- does not require the presence of these CSF-1-depen-
dent macrophage subsets, we conclude that separatedent macrophages (op/op). However, while IVIG is able
to protect lymphocyte-deficient mice from K/BxN arthri- subsets of macrophages are involved in the effector
response to antibodies and in IVIG protection.tis (Figure 3E and data not shown), it is unable to mediate
similar protection in CSF-1-dependent macrophage- To determine which effector cells are the targets of
IVIG protection, synovial infiltrates from K/BxN serum-deficient animals (Figure 3F). Histological examination
of op/op ankles demonstrated severe synovitis and neu- treated wt and op/op mice were analyzed for their cellu-
lar contents and FcRIIB expression in the presencetrophil infiltration at day 6 after K/BxN serum treatment,
with IVIG showing no protective effect (Figure 3G). This or absence of IVIG treatment (Figure 4). K/BxN serum
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Figure 3. IVIG Protection Is FcRIIB Dependent, and Different Macrophage Subsets Are Required for Disease Progression or IVIG Protection
in K/BxN Serum-Induced Arthritis
Mean results of arthritis score after injection of PBS (black squares), K/BxN serum alone (blue triangles), or IVIGK/BxN serum (red circles)
at day 0 into (A) BALB/c FcRIII/, (B) 129/B6 FcRI/ mice, (C) C57BL/6 FcRII/ (wt control is shown in inset), (D) BALB/c FcRII/,
(E) C57BL/6 IgH/, and (F) B6/C3H op/op mice (wt B6/C3H control is shown in inset) are presented. Three to five mice per group were used;
data is representative from two different experiments. (G) Hematoxylin-eosin staining of op/op ankle sections of K/BxN serum-treated or
IVIGK/BxN serum-treated mice at day 6, at low magnification (left panels) and high magnification (right panels). Severe synovitis and massive
infiltration of neutrophils is present in both conditions.
treatment results in a massive infiltration (104 cells/knee fluid (Figures 4A and 4B, middle panel). FcRIIB expres-
sion, detected with mAb Ly17.2, was increased approxi-joint fluid) of predominately GR-1 Mac-1 neutrophils
and to a lesser extent of F4/80 macrophages in both mately 1.7-fold on the F4/80 macrophages and 1.5-
fold on the MOMA-1 macrophages found in the wtwt and op/op mice (Figures 4A and 4B). In wt mice, these
macrophages are Mac-1 and GR-1, and a majority is synovial fluid but not in the op/op synovial fluid (Figures
4C and 4D). No induction was apparent on the infiltratingMOMA-1, in agreement with the infiltrates analyzed in
KRNxNOD F1 mice (Kouskoff et al., 1996). In contrast, neutrophils in either strain. IVIG treatment results, there-
fore, in a macrophage-specific induction of FcRIIB ex-MOMA-1 macrophages were virtually absent from in-
flamed op/op synovial fluids (numbers correspond to pression at the site of inflammation.
The main difference between wt and op/op mice inbackground staining), which also exhibit an increased
infiltration of GR-1 neutrophils and a reduced infiltra- the cellular contents of inflamed synovial fluids is the
presence of MOMA-1 macrophages, as GR-1 neutro-tion of F4/80 macrophages (Figure 4B). These macro-
phages were previously reported absent from the resting phils and F4/80 macrophages are present in joint infil-
trates of both strains. Supporting these results, op/opop/op synovium (Cecchini et al., 1994; Witmer-Pack et
al., 1993), providing an explanation for the reduced infil- mice were previously reported to have complete defects
in the MOMA-1 macrophages, but not in the F4/80tration of F4/80 macrophages in the inflamed synovial
space in op/op mice. In wt mice but not in op/op mice, macrophages, in the spleen (Cecchini et al., 1994;
Witmer-Pack et al., 1993; data not shown). MOMA-1IVIGK/BxN serum treatment results in a 6-fold de-
crease in the number of cells infiltrating the knee joint cells are therefore candidates to be the targets of the
Macrophages Enable IVIG Protection from Arthritis
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Figure 4. IVIG Induces Selective In Vivo Overexpression of FcRIIB on Infiltrating Macrophages in Wt Mice but Not in op/op Mice
(A and B) Wt BALB/c (A) or op/op mice (B) were injected with PBS, K/BxN serum alone, or IVIGK/BxN serum at day 0. Representative FACS
dot plot of knee joint cells stained with Mac-1 and GR-1 mAbs (left panels), GR-1, F4/80, or MOMA-1 in combination with Ly17.2 (right panels).
The percentages of cells in quadrants are indicated.
(C and D) Fold increase representation of Ly17.2 expression on synovial cellular subsets from IVIGK/BxN serum-treated mice compared to
K/BxN serum-treated mice at day 6 (the MFI of the IVIGK/BxN serum condition was divided by the MFI of K/BxN serum condition). Data is
representative from (C, left panel) three and (D) two independent experiments. (C, right panel) Synovial fluids were recovered individually from
wt BALB/c mice treated with K/BxN serum alone or IVIGK/BxN serum, and stained with mAbs MOMA-1 and Ly17.2. The MFI of Ly17.2
staining on MOMA-1 macrophages for five mice per group is indicated (diamonds), as well as the mean MFI (bar). The Student’s t test gave
a statistical difference of p  0.0002 of Ly17.2 staining between the two groups. Two independent experiments gave the same result.
anti-inflammatory activities of IVIG. To ascertain the in- from K/BxN serum alone-treated mice (CD86: MFI 53
and 161, respectively). Together, these results suggestduction of expression of FcRIIB on MOMA-1 macro-
phages in wt mice, synovial fluids were recovered indi- that the target of IVIG is the MOMA-1 FcRIIB macro-
phages found in the synovial space and indicate thatvidually from mice treated with K/BxN serum alone or
IVIGK/BxN serum. A statistical difference (p0.001) of these cells, by increasing FcRIIB expression, have
raised their threshold for activation by anti-GPI immuneFcRIIB expression was found between the two groups
(Figure 4C, right panel), confirming the induction ob- complexes. These results point to an essential role for
macrophages in the progression of the inflammatoryserved in the pooled synovial fluids experiments (Figure
4C, left panel). To further investigate the phenotype of response seen in this model of immune complex inflam-
mation and are consistent with the induction of FcRIIBthese MOMA-1 FcRIIBhigh macrophages infiltrating the
synovial fluid after IVIGK/BxN serum treatment, stain- on splenic macrophages by IVIG in the ITP model re-
ported previously (Samuelsson et al., 2001).ing with multiple macrophage-specific and activation
markers was performed (Figure 5). MOMA-1 FcRIIBhigh
macrophages are characteristic of inflamed tissue macro- Discussion
phages, expressing Mac-3, scavenger receptors (SR-A,
MARCO), and integrins (ICAM-1, VCAM-1). In contrast, The anti-inflammatory properties of IVIG have been
widely used in autoimmune diseases to attenuate dis-they express poorly complement receptors (CRI/CRII)
and the activation markers CD69 and CD86. Indeed, ease progression (Pyne et al., 2002). The protection ob-
served has now been demonstrated in two disparateCD86 expression on MOMA-1 macrophages isolated
from IVIGK/BxN serum-treated mice was 30% of the murine models to result from the ability of IVIG to induce
expression of the inhibitory IgG FcR, FcRIIB, on effectorlevel expressed on MOMA-1 macrophages isolated
Immunity
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Figure 5. Phenotype of MOMA-1 Ly17.2high
Macrophages Infiltrating the Knee Joints of
IVIGK/BxN Serum-Treated BALB/c Mice
Fifteen wt BALB/c mice were injected with
IVIG and K/BxN serum at day 0. Knee joint
cells were stained 5 min in the presence of 5
g/ml of 2.4G2 to prevent nonspecific binding
to Fc receptors, and then with FITC-labeled
MOMA-1 mAb and the indicated PE-labeled
mAbs (except staining performed with unla-
beled rat mAbs anti-SR-A, anti-ER-TR9, anti-
CD169, and anti-MARCO, which were used
in the absence of 2.4G2 and detected with
PE-labeled F(ab)2 anti-rat, followed by three
washings and staining with FITC-labeled anti-
MOMA-1 mAbs). Classification of the macro-
phage and activation markers in different categories are indicative and not absolute, as these markers are shared with other cells. *, staining
for nonmacrophage markers (B, T, mast, dendritic cell, leukocyte, neutrophil, fibroblast, respectively) were performed to ensure the macrophagic
nature of the MOMA-1 subset. As macrophages were found positive for FasL in synovial infiltrates in human RA patients, staining with anti-
FasL was also performed. Results shown are representative of two independent experiments. Abbreviations: Mφ, macrophage, BM-dMφ,
bone-marrow derived-macrophage.
macrophages, thereby raising the threshold required for is required to interact with the Fc fragment of IVIG. Un-
fortunately, testing the transferability of protection usinginducing macrophage activation and subsequent in-
flammatory sequelae (this report and Samuelsson et al., wt CSF-1-dependent macrophages cannot be at-
tempted as the defect in op/op is not cell autonomous2001). This mechanism appears to be independent both
of the specificity of the autoantibody and the site of but depends on environmental CSF-1 production (Marks
et al., 1984; Schmitz et al., 1986; Wiktor-Jedrzejczak etmacrophage activation and is likely to represent a gen-
eral mechanism for IVIG protection in antibody-triggered al., 1982). In other words, CSF-1-dependent macro-
phages transferred from a wild-type donor to the op/opautoimmune diseases. In the case of ITP, anti-platelet
antibodies opsonize platelets and engage FcRIII on recipient do not survive. MOMA-1 cells are likely to
bear a high-affinity receptor for this Fc fragment, whichsplenic macrophages to mediate thrombocytopenia
(Bussel, 2000). IVIG treatment leads to the induction of is distinct from the known canonical IgG Fc receptors.
A variety of molecules with homology to FcRs haveFcRIIB on these splenic macrophages and results in
protection from macrophage-mediated platelet clear- recently been described and could be candidates for
this unknown IVIG receptor (Davis et al., 2001).ance. In K/BxN-induced arthritis, immune complexes
composed of GPI and anti-GPI antibodies engage A model to account for the separable functions of
CSF-1-dependent and -independent macrophages inFcRIII on mast cells and macrophages in the synovium
to initiate an Arthus-type reaction resulting in neutrophil antibody-mediated inflammation and IVIG protection is
presented in Figure 6. In this model, antibody-triggeredinfiltration and joint destruction (Kouskoff et al., 1996;
Lee et al., 2002; Matsumoto et al., 1999). IVIG treatment inflammation is mediated by “effector” macrophages,
defined here as CSF-1-independent cells (F4/80results in the induction of FcRIIB on synovial macro-
phages, raising their threshold for immune complex ac- MOMA-1), through the crosslinking of the low-affinity
activation Fc receptor FcRIII by immune complexes ortivation and preventing subsequent inflammatory re-
sponses. In both cases it is the monomeric Fc fragment cytotoxic antibodies. This crosslinking of FcRIII leads
to the generation of effector responses such as phago-of IVIG that is responsible for the protective effect ob-
served. cytosis, cytokine, and chemokine production and the
hallmarks of an inflammatory response. IVIG, throughThe mechanism by which IVIG results in induction of
FcRIIB has been investigated in these two models of its Fc fragment, interacts with an Fc receptor on CSF-1-
dependent “sensor” macrophages (F4/80 MOMA-1), toautoimmunity, ITP and K/BxN-induced arthritis. Protec-
tion is dependent upon the presence of FcRIIB and result in the elaboration of mediator(s) capable of induc-
ing expression of the inhibitory FcRIIB receptor on theCSF-1-dependent macrophages deficient in the op/op
mouse. The presence of neither the high-affinity FcRI CSF-1-independent effector macrophages. This induc-
tion of FcRIIB on the effector macrophage raises thereceptor nor serum IgG is required for the protective
effect of IVIG. Insight into the mechanism of IVIG protec- threshold required to activate FcRIII and prevent im-
mune complex or cytotoxic antibody trigger effector celltion has come from the observation that op/op mice are
deficient in specific macrophage subsets, like MOMA-1 responses, thus conferring protection from pathogenic
autoantibodies and immune complexes. The innate re-macrophages (this report and as previously reported
[Cecchini et al., 1994; Witmer-Pack et al., 1993]). Inter- sponses conferred by CSF-1-dependent macrophages
are thus coupled to the antibody-mediated effectorestingly, the presence of these MOMA-1 macrophages
correlates with the increased expression of FcRIIB on mechanisms of CSF-1-independent macrophages to re-
sult in protection.infiltrating F4/80 macrophages in the arthritic joints.
Our conclusion based on the genetic data for the re- Studies in human RA (rheumatoid arthritis) further
support our conclusions that macrophages play an es-quirement for IVIG protection indicates that a separate
macrophage subset (MOMA-1), deficient in op/op mice sential role in the pathogenesis of inflammation ob-
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Figure 6. Proposed Model for the Mechanism of IVIG Protection in Autoantibody-Triggered Inflammatory Diseases
See text for details. Abbreviations: Mφ, macrophage; MZ, marginal zone; GPI, glucose-6-phosphate isomerase.
served in that chronic disease as well as providing that has evolved to prevent inappropriate activation of
additional validation for the K/BxN model for RA. Macro- inflammatory responses during IgG fluctuations in the
phages in the inflamed synovium and its synovial fluid serum. Such fluctuations could occur during an ongoing
have been shown to express FcRIII in both mice (Blom immune response or in microanatomic compartments
et al., 2000) and humans (Edwards et al., 1997; Nieto et in which localized concentrations of IgG may become
al., 2000) and are therefore sensitive to GPI-IC-mediated elevated. Induction of an inhibitory receptor would pro-
activation (Schaller et al., 2001). Macrophages play a vide a protective mechanism to prevent inappropriate
determinant role in arthritic pathogenesis, releasing in- effector cell activation in the absence of inflammatory
flammatory cytokines, and recruiting and activating second signal, such as IFN-, which upregulates FcRIII
neutrophils, thus amplifying the local inflammatory re- and downmodulates FcRIIB (Weinshank et al., 1988).
sponse (Kinne et al., 2000). IVIG treatment improves Perturbations in this pathway, as may occur in autoim-
clinical status in human arthritic syndromes (reviewed mune diseases, could lead to the unrestricted activation
in Pyne et al., 2002), resulting in decreased levels of of effector cells by immune complexes and result in
inflammatory cytokines (Muscat et al., 1995) and circu- states of chronic inflammation.
lating IC in the serum (Delire, 1994). As we demonstrate
in this study, IVIG protects mice from K/BxN serum-
Experimental Proceduresinduced arthritis by inverting the activation/inhibition
balance of Fc receptors on macrophages thus pre-
Miceventing IC activation of these effector cells. Interestingly,
NOD mice (6–8 weeks old) were obtained from Taconic Farms (Ger-
CSF-1 is produced by synovial fibroblasts, is present mantown, NY). BALB/c, C57BL/6 (B6), 129/B6, B6/C3H F1,
in inflammatory synovial fluid from human RA patients B6.IgH/, and B6/C3H.op/op mice (used in the ITP experiments)
(Kawaji et al., 1995; Ritchlin et al., 1994; Seitz et al., 1994), were obtained from The Jackson Laboratory (Bar Harbor, ME).
and was shown to promote macrophage infiltration and FcRI/ 129/B6 and FcRIII/ BALB/c mice were gifts from P.M.
Hogarth (The Austin Research Institute, Victoria, Australia) and T.proliferation in the joints (Bischof et al., 2000). Therefore,
Takai (Tohoku University, Sendai, Japan), respectively. FcRII/CSF-1-dependent macrophage subsets may also be re-
mice on the BALB/c and the C57BL/6 background were previouslysponsible for the protective effects of IVIG on autoanti-
generated in our laboratory. KRN TCR transgenic mice on a B6body-triggered inflammations in human disease.
background (K/B) were gifts from D. Mathis and C. Benoist (Harvard
The existence of a discrete pathway on specific mac- Medical School, Boston, MA) and were bred to NOD mice to gener-
rophage subsets to sense IgG Fc concentration and ate K/BxN mice. B6/C3H.op/op mice used in the arthritis experi-
respond by inducing expression of FcRIIB on effector ments were from J.W. Pollard (Albert Einstein College of Medicine,
Bronx, NY). All mice were used at 2 to 4 months of age.macrophages may reflect a homeostatic mechanism
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Antibodies was supported in part by grants from the NIH and the Alliance for
Lupus Research.Human intravenous  globulin (10% in 0.2 M glycine, chromatogra-
phy purified) was a kind gift of the Bayer Corporation, Pharmaceuti-
cal division (Elkhart, IN). A single dose of 1 g/kg was injected i.v. 1 Received: November 11, 2002
hr before the K/BxN serum injection in all experiments, except as Revised: January 23, 2003
described in Figure 1B where IVIG was injected 48 hr after the K/BxN Accepted: January 31, 2003
serum injection. Digestion of human IVIG was performed with 0.5 Published: April 15, 2003
mg/ml papain (Roche Molecular Biochemicals, Indianapolis, IN) for
1 hr at 37C, and stopped by the addition 2.5 mg/ml iodoacetamide. References
Fab and Fc resulting fragments were separated from nondigested
IVIG on a HiPrep 26/600 S-200HR column (Pharmacia, Piscataway, Bischof, R.J., Zafiropoulos, D., Hamilton, J.A., and Campbell, I.K.
NJ). Fc fragments were separated from Fab fragments using a ProtG (2000). Exacerbation of acute inflammatory arthritis by the colony-
column (Pharmacia). Fragment purity was checked by immunoblot- stimulating factors CSF-1 and granulocyte macrophage (GM)-CSF:
ting using anti-human IgG Fab or Fc-specific antibodies (Sigma, St. evidence of macrophage infiltration and local proliferation. Clin. Exp.
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